Chemomab Therapeutics to Present at H.C. Wainwright 28th Annual Global Investor ConferenceGlobeNewsWire • 08/31/26
Chemomab Therapeutics Announces Second Quarter 2026 Financial Results and Provides Corporate UpdateGlobeNewsWire • 08/19/26
Chemomab Therapeutics and Precision Medicine Pioneer Scipher Medicine Announce Merger Agreement to Advance Nebokitug in an AI-Powered Phase 2 Trial in Rheumatoid ArthritisGlobeNewsWire • 07/08/26
Chemomab Therapeutics Announces First Quarter 2026 Financial Results and Provides Corporate UpdateGlobeNewsWire • 05/14/26
Chemomab Therapeutics Announces Year End and Fourth Quarter 2025 Financial Results and Provides a Corporate UpdateGlobeNewsWire • 03/19/26
Chemomab Therapeutics to Participate in Oppenheimer 36th Annual Healthcare Life Sciences ConferenceGlobeNewsWire • 02/17/26
Chemomab Therapeutics Announces Nebokitug Phase 2 SPRING Trial Results in Primary Sclerosing Cholangitis Published in the American Journal of GastroenterologyGlobeNewsWire • 12/02/25
Chemomab Therapeutics Announces Third Quarter 2025 Financial Results and Provides Corporate UpdateGlobeNewsWire • 11/20/25
Chemomab Announces Multiple Presentations at AASLD The Liver Meeting® 2025 Featuring Clinical Data from the Nebokitug Phase 2 Trial in Primary Sclerosing CholangitisGlobeNewsWire • 11/06/25
Chemomab Therapeutics to Present at H.C. Wainwright 27th Annual Global Investment ConferenceGlobeNewsWire • 08/21/25
Chemomab Therapeutics Announces Second Quarter 2025 Financial Results and Provides Corporate UpdateGlobeNewsWire • 08/14/25
Chemomab Announces Oral Presentation of Positive Nebokitug Phase 2 Clinical Data in Primary Sclerosing Cholangitis at BSG Live'25GlobeNewsWire • 06/30/25
Chemomab Reports Positive Feedback From Two Recent FDA Meetings Supporting Phase 3 Advancement of Nebokitug in Primary Sclerosing CholangitisGlobeNewsWire • 06/11/25
Chemomab Announces New Patent Awards for Its First-in-Class Agent Nebokitug that is Positioned to Potentially Become the First Approved Drug for Primary Sclerosing CholangitisGlobeNewsWire • 06/03/25
Chemomab Therapeutics Announces First Quarter 2025 Financial Results and Provides Corporate UpdateGlobeNewsWire • 05/15/25
Chemomab Announces Presentation of Positive Nebokitug Phase 2 Clinical Data in Primary Sclerosing Cholangitis in Distinguished Plenary Session at DDW 2025GlobeNewsWire • 05/05/25
Chemomab Reports New Positive Clinical Data at EASL 2025 Supporting Nebokitug's Impact in Primary Sclerosing Cholangitis and Related DiseasesGlobeNewsWire • 04/28/25
Chemomab Therapeutics to Present Nebokitug Clinical Data at Upcoming Scientific ConferencesGlobeNewsWire • 04/21/25
Chemomab Therapeutics' Touts Positive Data From Experimental Drug For Chronic Liver DiseaseBenzinga • 03/27/25
Chemomab Reports Positive Results in Nebokitug Phase 2 PSC Open Label Extension Trial Showing Continued Broad and Substantial Improvements in Key Liver BiomarkersGlobeNewsWire • 03/27/25